Tumor Glycolysis Inhibition

Tumor glycolysis inhibition targets the metabolic pathway by which cancer cells preferentially metabolize glucose to lactate, even in the presence of oxygen—a phenomenon known as the Warburg effect. This metabolic reprogramming supports rapid tumor growth, survival, metastasis, and resistance to therapy by providing both energy (ATP) and biosynthetic precursors necessary for proliferation. Therapeutic strategies involve direct inhibition of key glycolytic enzymes or targeting regulatory pathways that control glucose metabolism.

Other names

Warburg Effect InhibitionInhibition of Aerobic Glycolysis in Cancer Cells

Inhibition of key enzymes in the glycolytic pathway, leading to reduced ATP production, impaired biosynthesis, and altered tumor microenvironment. Indirect inhibition via targeting upstream regulatory pathways (e.g., mTOR).